1.0 2009-07-21 20:27:02 UTC 2026-05-14 16:40:30 UTC T3D2809 Oxycodone SmallMolecule Oxycodone belongs to the phenanthrenes and derivatives, a class of benzenoids within the organic compounds. This exogenous compound has the formula C18H21NO4 and an average molecular weight of 315.36 g/mol. At room temperature, it exists as a solid. It is used as an opioid analgesic, mu-opioid receptor agonist, analgesic, and antitussive (PMC7941040). It is used as a treatment for pain (PMC7012325) and chronic pain (PMC6205722), though it is associated with lethargy and depression (PMC7012325). Oxycodone targets the mu-type opioid receptor (OPRM1), kappa-type opioid receptor (OPRK1), and delta-type opioid receptor (OPRD1), while also acting as an inhibitor of the voltage-dependent N-type calcium channel subunit alpha-1B (CACNA1B). Within the central nervous system (CNS), it acts as a weak agonist at the mu, kappa, and delta opioid receptors. It primarily affects mu-type opioid receptors, which are coupled with G-protein receptors and function as modulators of synaptic transmission via G-proteins that activate effector proteins. Binding stimulates the exchange of GTP for GDP on the G-protein complex. Because the effector system consists of cAMP and adenylate cyclase located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Oxycodone is recorded in several sources, including analgesics, drinking water, the preparation of vinegar, and household cleaning and consumer products such as pipe accessories, other smoking requisites, and non-electric simulated smoking devices. It is also found in electrical and electronic equipment, including antennas, amplifiers, relays, auxiliary devices, and line transmission systems. Recorded exposure routes include oral and rectal administration. Drug Synthetic Toxin Organic Compound Amine Ether Drug Analgesic, Opioid Narcotic Antitussive Agent Opiate Agonist Metabolite Synthetic Compound Human Neurotoxin (-)-14-Hydroxydihydrocodeinone 4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one 4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one Dihydro-14-hydroxycodeinone Dihydrohydroxycodeinone Dihydrohydroxycondeinone Dihydrone Dihydroxycodeinone Oxanest Oxecta Oxicodona Oxycodonum Oxycontin OxyIR PTI-821 Roxicodone C18H21NO4 315.3636 315.147058165 (1S,5R,13R,17S)-17-hydroxy-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one (1S,5R,13R,17S)-17-hydroxy-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one 76-42-6 [H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O InChI=1S/C18H21NO4/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10/h3-4,13,16,21H,5-9H2,1-2H3/t13-,16+,17+,18-/m1/s1 BRUQQQPBMZOVGD-XFKAJCMBSA-N Organic compounds Benzenoids Phenanthrenes and derivatives Phenanthrenes and derivatives 1,2-aminoalcohols Alkyl aryl ethers Anisoles Aralkylamines Azacyclic compounds Coumarans Cyclic alcohols and derivatives Hydrocarbon derivatives Isoquinolones and derivatives Ketones Organic oxides Organopnictogen compounds Oxacyclic compounds Piperidines Tertiary alcohols Tetralins Trialkylamines 1,2-aminoalcohol Alcohol Alkyl aryl ether Amine Anisole Aralkylamine Aromatic heteropolycyclic compound Azacycle Carbonyl group Coumaran Cyclic alcohol Ether Hydrocarbon derivative Isoquinolone Ketone Organic nitrogen compound Organic oxide Organic oxygen compound Organoheterocyclic compound Organonitrogen compound Organooxygen compound Organopnictogen compound Oxacycle Phenanthrene Piperidine Tertiary alcohol Tertiary aliphatic amine Tertiary amine Tetralin Aromatic heteropolycyclic compounds organic heteropentacyclic compound Detected and Not Quantified Exogenous Cytoplasm Extracellular Membrane Oxycodone Action Pathway SMP0000409 Oxycodone Opioid Agonist Action Pathway SMP0125024 Oxycodone Drug Metabolism Action Pathway SMP0142951 Oxycodone Predicted Metabolism Pathway SMP0174781 Solid White powder. melting_point 219°C solubility 100 mg/ml logp 0.3 logp 1.04 ALOGPS logs -1.75 ALOGPS solubility 5.59e+00 g/l ALOGPS logp 1.03 ChemAxon pka_strongest_acidic 13.56 ChemAxon pka_strongest_basic 8.21 ChemAxon iupac (1S,5R,13R,17S)-17-hydroxy-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one ChemAxon average_mass 315.3636 ChemAxon mono_mass 315.147058165 ChemAxon smiles [H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O ChemAxon formula C18H21NO4 ChemAxon inchi InChI=1S/C18H21NO4/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10/h3-4,13,16,21H,5-9H2,1-2H3/t13-,16+,17+,18-/m1/s1 ChemAxon inchikey BRUQQQPBMZOVGD-XFKAJCMBSA-N ChemAxon polar_surface_area 59 ChemAxon refractivity 84.04 ChemAxon polarizability 32.79 ChemAxon rotatable_bond_count 1 ChemAxon acceptor_count 5 ChemAxon donor_count 1 ChemAxon physiological_charge 1 ChemAxon formal_charge 0 ChemAxon Oral; enteral (rectal). Well absorbed with an oral bioavailability of 60% to 87% Oxycodone acts as a weak agonist at mu, kappa, and delta opioid receptors within the central nervous system (CNS). Oxycodone primarily affects mu-type opioid receptors, which are coupled with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids such as oxycodone also inhibit the release of vasopressin, somatostatin, insulin, and glucagon. Opioids close N-type voltage-operated calcium channels (kappa-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (mu and delta receptor agonist). This results in hyperpolarization and reduced neuronal excitability. Hepatic Route of Elimination: Oxycodone and its metabolites are excreted primarily via the kidney. Half Life: 4.5 hours No indication of carcinogenicity to humans (not listed by IARC). For the treatment of diarrhoea, pulmonary oedema and for the relief of moderate to moderately severe pain. #<HealthEffect::ActiveRecord_Associations_CollectionProxy:0x00007f7265f0f0a8> Symptoms of overdose include respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, bradycardia, hypotension, and death. To treat Oxycodone overdose, primary attention should be given to the reestablishment of a patent airway and institution of assisted or controlled ventilation. Supportive measures (including oxygen and vasopressors) should be employed in the management of circulatory shock and pulmonary edema accompanying overdose as indicated. Cardiac arrest or arrhythmias may require cardiac massage or defibrillation. The narcotic antagonists, naloxone or nalmefene, are specific antidotes for opioid overdose. Opioid antagonists should not be administered in the absence of clinically significant respiratory or circulatory depression secondary to Oxycodone overdose. If needed the appropriate dose of naloxone hydrochloride or nalmefene should be administered simultaneously with efforts at respiratory resuscitation (see package insert for each drug for the details). Since the duration of action of oxycodone may exceed that of the antagonist, the patient should be kept under continued surveillance and repeated doses of the antagonist should be administered as needed to maintain adequate respiration. Gastric emptying may be useful in removing unabsorbed drug. (L1712) DB00497 HMDB14640 5284603 CHEMBL656 4447649 C08018 7852 Oxycodone Oxycodone 17525040 18039433 Drugs.com: http://www.drugs.com/cons/Oxycodone.html RxList: The Internet Drug Index (2009).: http://www.rxlist.com/ BE0000632 Oxycodone acts as a weak agonist at mu, kappa, and delta opioid receptors within the central nervous system (CNS). Oxycodone primarily affects mu-type opioid receptors, which are coupled with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids such as oxycodone also inhibit the release of vasopressin, somatostatin, insulin, and glucagon. Opioids close N-type voltage-operated calcium channels (kappa-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (mu and delta receptor agonist). This results in hyperpolarization and reduced neuronal excitability. BE0000770 Oxycodone acts as a weak agonist at mu, kappa, and delta opioid receptors within the central nervous system (CNS). Oxycodone primarily affects mu-type opioid receptors, which are coupled with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids such as oxycodone also inhibit the release of vasopressin, somatostatin, insulin, and glucagon. Opioids close N-type voltage-operated calcium channels (kappa-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (mu and delta receptor agonist). This results in hyperpolarization and reduced neuronal excitability. BE0000420 Oxycodone acts as a weak agonist at mu, kappa, and delta opioid receptors within the central nervous system (CNS). Oxycodone primarily affects mu-type opioid receptors, which are coupled with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids such as oxycodone also inhibit the release of vasopressin, somatostatin, insulin, and glucagon. Opioids close N-type voltage-operated calcium channels (kappa-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (mu and delta receptor agonist). This results in hyperpolarization and reduced neuronal excitability. BE0004899 BE0004879 BE0002226